SIGA bags $28 million of international orders for oral TPOXX

13 July 2022

SIGA Technologies (Nasdaq: SIGA) saw its shares gain almost 8% to $14.05 today, after it announced around $28 million of procurement orders for its oral TPOXX (tecovirimat).

Oral TPOXX is approved in Canada and the USA for the treatment of smallpox but has shown efficacy in treating patients with the monkeypox virus, which is endemic in some African countries, but the incidence of which has been increasing in Europe and North America.

Danish vaccine developer Bavarian Nordic (OMX: BAVA) has also been securing contracts to supply its Imvanex smallpox vaccine in response to new cases of monkeypox evolving during May 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK